BlackRock Amends Cytek Biosciences Stake as of Dec 31, 2023
Ticker: CTKB · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1831915
| Field | Detail |
|---|---|
| Company | Cytek Biosciences, Inc. (CTKB) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, portfolio-update
TL;DR
**BlackRock just updated its Cytek Biosciences stake, watch for potential market reaction.**
AI Summary
BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, indicating a change in its ownership of Cytek Biosciences, Inc. common stock as of December 31, 2023. This amendment (Amendment No. 2) updates their previous filing, signaling a potential adjustment in their investment strategy or a rebalancing of their portfolio. For investors, this matters because BlackRock is a major institutional investor, and changes in their holdings can sometimes signal their outlook on the stock's future performance or the company's fundamentals.
Why It Matters
This filing shows BlackRock, a significant institutional investor, has updated its position in Cytek Biosciences, which could influence market perception and investor confidence.
Risk Assessment
Risk Level: low — This is a routine amendment filing by a large institutional investor, not indicating any immediate severe risk.
Analyst Insight
Investors should review the full SC 13G/A filing once available to understand the specific changes in BlackRock's holdings (e.g., increase or decrease in shares) and consider if this aligns with their own investment thesis for Cytek Biosciences.
Key Numbers
- 23285D109 — CUSIP Number (identifies Cytek Biosciences' Common Stock)
- 0001364742 — BlackRock Inc. CIK (Central Index Key for BlackRock Inc.)
- 0001831915 — Cytek Biosciences, Inc. CIK (Central Index Key for Cytek Biosciences, Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the institutional investor filing the SC 13G/A
- Cytek Biosciences, Inc. (company) — the subject company whose common stock is being reported
- December 31, 2023 (date) — the date of the event requiring the filing
- January 23, 2024 (date) — the filing date of the SC 13G/A
- Amendment No. 2 (number) — the specific amendment number for this filing
Forward-Looking Statements
- BlackRock's updated stake in Cytek Biosciences may lead to increased investor scrutiny of Cytek's upcoming financial reports. (Cytek Biosciences, Inc.) — medium confidence, target: Q1 2024 Earnings Report
FAQ
What type of filing is this and what does it generally indicate?
This is an SC 13G/A filing, which is an amendment to a Schedule 13G. It indicates that an institutional investor, in this case BlackRock Inc., has updated its beneficial ownership of 5% or more of a company's stock, Cytek Biosciences, Inc., as of December 31, 2023.
Who is the filer of this document and what is their primary business?
The filer is BlackRock Inc., a company primarily involved in 'SECURITY BROKERS, DEALERS & FLOTATION COMPANIES' according to its Standard Industrial Classification (SIC) code 6211. Their business address is 50 Hudson Yards, New York, NY 10001.
What is the subject company of this filing and what is its business?
The subject company is Cytek Biosciences, Inc., which falls under the 'LABORATORY ANALYTICAL INSTRUMENTS' (SIC 3826) industry. Their business address is 47215 Lakeview Boulevard, Fremont, CA 94538.
What is the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' is December 31, 2023, as stated in the filing. This is the date as of which the ownership information is being reported.
What rule under the Securities Exchange Act of 1934 is this Schedule 13G filed under?
This Schedule 13G is filed under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'X' in the appropriate box on the cover page.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Cytek Biosciences, Inc. (CTKB).